MedTrace Logo

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)

NCT02656212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-04-28

No results posted yet for this study

Summary

This will be a double-blind, randomized, placebo-controlled, single dose study of (+)- epicatechin with one 30mg dose/day for a total of 7 days

Conditions

  • Pre-diabetes

Interventions

DRUG

epicatechin

30 mg (+)-epicatechin, taken orally, one pill/day in the morning

DRUG

Placebo

Placebo pill, taken orally, one pill/day in the morning

Sponsors & Collaborators

  • San Diego Veterans Healthcare System

    collaborator FED

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • University of California, San Diego

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • Veterans Medical Research Foundation

    lead OTHER

Principal Investigators

  • Robert R Henry, MD · San Diego Veterans Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656212 on ClinicalTrials.gov